Picture of Dynavax Technologies logo

DVAX — Dynavax Technologies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Dynavax Technologies Corp expected to post a loss of 9 cents a share - Earnings Preview

* Dynavax Technologies Corp  DVAX.OQ   DVAX.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
3. 
    * The Emeryville California-based  company is expected to
report 
a 81.1% decrease in revenue to $48.38 million from $256.46
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Dynavax
Technologies Corp
is for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dynavax
Technologies Corp is $24.5​, above​ its last closing price
of $13.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.13       -0.13      -0.19     Missed  -43.4
 Dec. 31 2023  0.43        0.43       0.45      Beat    5.3
 Sep. 30 2022  0.34        0.33       0.43      Beat    31.3​
 Jun. 30 2022  0.22        0.22       0.87      Beat    295.5
 ​​Mar.        0.24        0.24       0.22      Missed  -8.3
 31 2022                                                
 Dec. 31 2021  0.61        0.64       0.55      Missed  -14.1​
 Sep. 30 2021  0.03        0.05       -0.24     Missed  -625.5
 Jun. 30 2021  -0.05       -0.04      0.02      Beat    155.1
 This summary was machine generated August 2 at 02:07 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Dynavax Technologies

See all news